Abbott To Take Over St Jude in $25 bln Mega-Cardio Deal

Abbott Laboratories to take over St Jude Medical
share Share

Abbott Laboratories is taking over St. Jude Medical Inc. in a deal worth $25 bln that will create a giant in the cardio-related devices market.

The two NYSE-listed companies said in a joint announcement that the combination will “create a premier medical device leader and strengthen Abbott’s long-term growth potential.”

They added that the merged company will consolidate St. Jude’s strong positions in heart-failure devices, heart catheters and defibrillators with Abbott’s strength in coronary intervention and heart-valve repair.

Under the deal, Abbott agreed to swap $46.75 in cash and 0.8708 shares for each St. Jude share, the Wall Street Journal reported. The offer values each St. Jude share at about $85, representing a 37 per cent premium to the stock’s closing price Wednesday.

Shares of Abbott fell 7 per cent to $40.60 in early trading, while St. Jude rose 25 per cent to $77.70, the WSJ said. The merged company will have annual cardiovascular sales of $8.7 bln and the deal is expected to be concluded in the final quarter of the year.

The merger comes at a time of growing concern of heart disease in the U.S. According to the two companies, more than 40 per cent of adults in the U.S. are expected to have one or more forms of heart disease by 2040.

Abbott CEO Miles White told analysts in a conference call that after the deal, the merged company would be better positions to compete in an increasingly consolidated U.S. healthcare market as hospitals grow and push for batter prices to keep their own costs down.

On the other hand, Reuters reported that the deal “raises doubts that Abbott will go through with its purchase of diagnostics company Alere Inc, which is under federal investigation for its sales practices.”

That deal, announced in February, would be worth $5.8 bln and would allow Abbott to become the leader in point-of-care diagnostic testing.

Abbott CEO Miles White last week declined to respond directly to a question on the Alere agreement, fueling speculation the deal might not close, Reuters said. 

Published on : Thu, 28 Apr 2016

Related Articles

New reports from EuroPCR 2016 reveal that half of transcatheter heart valves undergo degeneration within 10 years. Findings from... Read more

Despite widespread ecardiology applications, research is showing smaller effects as assessment becomes more robust. It is becoming... Read more

Computer graphic, downloading team spirit, credit Pixabay

The focus of the European Society of Cardiology Congress (ESC) is “The Heart Team”. It highlights the importance of teamwork... Read more

Abbott To Take Over St Jude in $25 bln Mega-Cardio Deal, Alere, cardiovascular, heart failure, catheter, defibrillator, coronary intervention, heart valve, merger, takeover Abbott To Take Over St Jude in $25 bln Mega-Cardio Deal

No comment

Please login to leave a comment...

Highlighted Products